Crinetics Pharmaceuticals (CRNX) Stock Price, Quote, News & History | Benzinga

Crinetics Pharmaceuticals Inc (CRNX) Stock Price, Quote, News & History

CRNXNASDAQ

Trade with Public

Trade with Public

$84.70

0.260.31%

At close: Aug 14, 5:00 PM EST

$84.45

-0.25-0.3%

After Hours: 9:28 AM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$84.38

Close

$84.70

Volume / Avg.

2.28M / 3.70M

Day Range

$84.36 - $84.70

52 Wk Range

28.62 - 84.71

Market Cap

$8.94B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

90

Short Interest

6.49%

Days to Cover

1.78

Recent Crinetics Pharmaceuticals, Inc. News

Top 3 Health Care Stocks That May Implode In August

3 health care stocks with high momentum could be overbought. Crinetics Pharmaceuticals (CRNX) has RSI of 90.6, Alamar Biosciences (ALMR) at 86.8, and Halozyme Therapeutics (HALO) at 81.7.

Avi Kapoor

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.

Piero Cingari

Benzinga Bulls and Bears: Penguin Solutions, Draftkings, Palantir — And Stocks End Week With Solid Gains

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.

Benzinga Senior Editor

Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’

The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.

Avi Kapoor

Nasdaq Dips Over 300 Points as Chip Stocks Fall: Investor Sentiment Weakens, Greed Index In 'Fear' Zone

Market sentiment slightly declines as Nasdaq falls. Crinetics shares soar, Rivian shares dip. Trade deficit rises.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-422.52M

Investing Cash Flow (TTM)

-4.15M

Financing Cash Flow (TTM)

427.92M

Free Cash Flow (TTM)

-425.18M

Capital Expenditure (TTM)

-2.66M

Net Change in Cash (TTM)

1.25M

Analyst Trends and Forecast

0

0

0

0

Mar

0

0

0

0

Apr

2

May

1

Jun

2

3

Jul

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.9

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$7.80B

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

199.80

PB Ratio (TTM)

7.52

Earnings Yield % (TTM)

-5.98%

Earnings Yield % (FWD)

-5.64%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$11.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$55.50M

Debt to Equity

0.04

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$84.38

Close

$84.70

Volume / Avg.

2.28M / 3.70M

Day Range

$84.36 - $84.70

52 Wk Range

28.62 - 84.71

Market Cap

$8.94B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

90

Short Interest

6.49%

Days to Cover

1.78

About

Sector

Health Care

Industry

Pharmaceuticals

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltu...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Crinetics Pharmaceuticals (CRNX) stock?

A

You can purchase shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Crinetics Pharmaceuticals (CRNX) competitors?

A

Other companies in Crinetics Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).

Q

What is the forecast, or price target, for Crinetics Pharmaceuticals (CRNX) stock?

A

Crinetics Pharmaceuticals has a consensus price target of $81.63.

Q

What is the current price for Crinetics Pharmaceuticals (CRNX)?

A

The stock price for Crinetics Pharmaceuticals (NASDAQ: CRNX) is $84.45 last updated August 14, 2026 at 9:28 AM EDT.

Q

Does Crinetics Pharmaceuticals (CRNX) pay a dividend?

A

There are no upcoming dividends for Crinetics Pharmaceuticals.

Q

When is Crinetics Pharmaceuticals (NASDAQ:CRNX) reporting earnings?

A

Crinetics Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Crinetics Pharmaceuticals (CRNX) going to split?

A

There is no upcoming split for Crinetics Pharmaceuticals.

Q

What sector and industry does Crinetics Pharmaceuticals (CRNX) operate in?

A

Crinetics Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.